Verena Briner - Novartis AG Insider

NVS -- USA Stock  

USD 78.70  0.61  0.78%

Non-Executive Independent Member of the Board
Dr. Verena A. Briner, M.D., serves as NonExecutive Independent Member of the Board of Novartis AG since 2013. Dr. Briner is professor of internal medicine at the Universitaet Basel, Switzerland, and chief medical officer and head of the department of medicine at the Lucerne Cantonal Hospital in Switzerland. She is a member of several medical and ethical institutions and commissions, including the board of the Foundation for the Development of Internal Medicine in Europe, the senate of the Swiss Academy of Medical Sciences, and the supervisory group for personalized medicine of the Centre for Technology Assessment TASWISS. She also is a member and former president of the Swiss Society of Internal Medicine
Age: 64  Executive Since 2013      
41 61 324 1111
Briner graduated from the Universitaet Basel with an M.D. in 1978, and has a specialized degree in internal medicine and nephrology from the Swiss Medical Association. She has received several prestigious scholarships and scientific grants, including the President?s Grant of the Society of General Internal Medicine in 2011, and is an honorary fellow of the American College of Physicians, the European Federation of Internal Medicine, the Polish Association of Internal Medicine, and the Swiss Society of General Internal Medicine. She was chief medical officer and department head at Swiss hospital; former president of Swiss medical society; member of various medical and ethical institutions and commissions.

Management Efficiency

The company has Return on Asset of 4.65 % which means that on every $100 spent on asset it made $4.65 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.62 % implying that it generated $11.62 on every 100 dollars invested.
The company has 34.11 B in debt with debt to equity (D/E) ratio of 47.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Novartis AG has Current Ratio of 1.15 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Entity Summary

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG operates under Drug Manufacturers - Major classification in USA and traded on New York Stock Exchange. It employs 124000 people.Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in SWITZERLAND and employs 124,000 people. Novartis AG was previously known as Novartis AG and was traded on OTC Market under the symbol NVSEF. Novartis AG is listed under Pharmaceutical Products category by Fama And French industry classification.

Novartis AG Leadership Team

Joerg Reinhardt, Chairman, Ph.D
Ton Buechner, Director, MBA
Paul Hudson, CEO
Verena Briner, Executive
Brian McNamara, Executive
Michele Galen, Executive
Charles Sawyers, Executive, Ph.D
Chris Ilsley, CEO
Steven Baert, Executive, MBA
Dimitri Azar, Director, MBA
Richard Francis, Executive
Frans Houten, Director
Nancy Andrews, Director, Ph.D
Enrico Vanni, Director, MBA
Pierre Landolt, Director
Elizabeth Doherty, Director
Andre Wyss, President
Bruno Strigini, CEO
Erwin Vanhaecke, Executive, Ph.D
Vasant Narasimhan, Executive
Michael Ball, CEO, MBA
Elizabeth Barrett, CEO, MBA
Jeffrey George, Executive, MBA
Mark Fishman, President, Ph.D
Charlotte PamerWieser, Executive
Shannon Klinger, Executive
Peter Kornicker, Executive, Ph.D
Andreas Planta, Director
Joseph Jimenez, CEO, MBA
Samir Shah, Executive
Ulrich Lehner, Chairman, MBA
William Winters, Executive, MBA
David Epstein, Executive, MBA
Ann Fudge, Director, MBA
Srikant Datar, Director, MBA
George Gunn, Executive, Ph.D
Paul Arkel, Executive
James Bradner, President
Felix Ehrat, Executive
Harry Kirsch, CFO
Andrin Oswald, Executive, Ph.D

Stock Performance Indicators

Current Sentiment - NVS

Novartis AG Investor Sentiment
Predominant part of Macroaxis users are now bullish on Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.